-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Efficacy of deoxyspergualine for antibody-mediated rejection and proteinuria after kidney transplantation
Case report
(2000) Views (447) Full article downloads
Authors: Hideki Ishida, Kazunari Tanabe
Published Date June 2008
Volume 2008:4(3) Pages 641 - 644
DOI: http://dx.doi.org/10.2147/TCRM.S2499
Hideki Ishida, Kazunari Tanabe
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
Abstract: A patient showing antibody-mediated rejection (AMR) with severe vasculitis, and massive proteinuria after kidney transplantation was treated with deoxyspergualine (DSG, Spanidin®, Nippon Kayaku). DSG showed marked efficacy for this patient’s symptoms. We report on a patient for whom DSG was effective against AMR after renal transplantation.
Keywords: deoxyspergualine (DSG), vascular rejection, antihuman leukocyte antigen (HLA) antibody
Readers of this article also read:
Moderate and severe plaque psoriasis: cost-of-illness study in Italy
Nonlinear analysis of the heartbeats in public patient ECGs using an automated PD2i algorithm for risk stratification of arrhythmic death
Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time
Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug
Antihypertensive effects of astaxanthin
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
